A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
Novo shares tumble by double digits on grim sales outlook
Novo shares tumble by double digits on grim sales outlook
Lilly soars again as fast-selling weight loss drugs top Wall Street projections
Lilly soars again as fast-selling weight loss drugs top Wall Street projections
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
Pfizer dips on new data for obesity drug acquired in $10B deal
Pfizer dips on new data for obesity drug acquired in $10B deal
FDA launches ‘PreCheck’ program; AstraZeneca, Acadia drugs set back
FDA launches ‘PreCheck’ program; AstraZeneca, Acadia drugs set back
Novo combination obesity shot meets goal in diabetes trial
Novo combination obesity shot meets goal in diabetes trial
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
GSK walks away from pioneering Wave RNA editing drug
GSK walks away from pioneering Wave RNA editing drug
Building a robust in-process testing plan for cell therapy manufacturing success
Building a robust in-process testing plan for cell therapy manufacturing success
Amgen gives up on its once-prized eczema drug
Amgen gives up on its once-prized eczema drug
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
Politicization runs deeper than ever at FDA, risking long-term impacts
Politicization runs deeper than ever at FDA, risking long-term impacts
The biopharma industry outlook on 2026: Optimism and tension
The biopharma industry outlook on 2026: Optimism and tension
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
AstraZeneca strengthens China ties with planned $15B investment
AstraZeneca strengthens China ties with planned $15B investment
Tenpoint wins FDA nod for combination presbyopia eye drop
Tenpoint wins FDA nod for combination presbyopia eye drop
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page